PL1699480T3 - Allogeniczny przeciwnowotworowy czynnik terapeutyczny - Google Patents

Allogeniczny przeciwnowotworowy czynnik terapeutyczny

Info

Publication number: PL1699480T3
Authority: PL; Poland
Prior art keywords: therapeutic agent; allogeneic tumor; tumor therapeutic; vaccine; tumor cells
Prior art date: 2003-12-30

Application number

PL04728317T

Other languages

English (en)

Inventor

Tomislav Dobric

Burghardt Wittig

Manuel Schmidt

Original Assignee

Mologen Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-30

Filing date

2004-04-20

Publication date

2011-11-30

2004-04-20 Application filed by Mologen Ag filed Critical Mologen Ag

2011-11-30 Publication of PL1699480T3 publication Critical patent/PL1699480T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL04728317T 2003-12-30 2004-04-20 Allogeniczny przeciwnowotworowy czynnik terapeutyczny PL1699480T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE0304299		2003-12-30
EP04728317A EP1699480B1 (de)	2003-12-30	2004-04-20	Allogenes tumortherapeutikum
PCT/DE2004/000859 WO2005063280A1 (de)	2003-12-30	2004-04-20	Allogenes tumortherapeutikum

Publications (1)

Publication Number	Publication Date
PL1699480T3 true PL1699480T3 (pl)	2011-11-30

Family

ID=34716109

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04728317T PL1699480T3 (pl)	2003-12-30	2004-04-20	Allogeniczny przeciwnowotworowy czynnik terapeutyczny

Country Status (12)

Country	Link
US (2)	US7635468B2 (pl)
EP (1)	EP1699480B1 (pl)
JP (1)	JP4945247B2 (pl)
CN (3)	CN102994515A (pl)
AT (1)	ATE512668T1 (pl)
BR (1)	BRPI0418157A (pl)
DK (1)	DK1699480T3 (pl)
ES (1)	ES2366694T3 (pl)
PL (1)	PL1699480T3 (pl)
PT (1)	PT1699480E (pl)
RU (1)	RU2354694C2 (pl)
WO (1)	WO2005063280A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2354694C2 (ru) *	2003-12-30	2009-05-10	Мологен Аг	Аллогенное противоопухолевое терапевтическое средство
WO2006015560A1 (de) *	2004-08-09	2006-02-16	Mologen Ag	Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
JP2009506780A (ja) *	2005-09-08	2009-02-19	モロゲン・アーゲー	インビトロ免疫測定における機能物（ｆｕｎｃｔｉｏｎａｌ）
PT2027266E (pt) *	2006-05-11	2011-03-14	Mologen Ag	Multímero para a imunoestimulação
CN101199862B (zh) *	2007-12-19	2011-07-06	北京大学第三医院	B7-1、cd40l质粒混合物
GB2483462A (en) *	2010-09-08	2012-03-14	Mologen Ag	Use of a dumbbell-shaped DNA construct for the treatment of cancer through jet-injection administration
GB2523187A (en) *	2014-02-18	2015-08-19	Mologen Ag	Covalently closed non-coding immunomodulatory DNA construct
CN106459991B (zh) *	2014-04-07	2021-03-05	洛孔法尔马有限公司	新型药剂及其用途
SMT202100094T1 (it)	2014-12-31	2021-03-15	Checkmate Pharmaceuticals Inc	Immunoterapia anti-tumorale combinata
LU92821B1 (en)	2015-09-09	2017-03-20	Mologen Ag	Combination comprising immunostimulatory oligonucleotides
GB2542425A (en)	2015-09-21	2017-03-22	Mologen Ag	Means for the treatment of HIV
EP3436066A1 (en)	2016-04-01	2019-02-06	Checkmate Pharmaceuticals, Inc.	Fc receptor-mediated drug delivery
US10731128B2 (en)	2016-11-22	2020-08-04	Alloplex Biotherapeutics, Inc.	Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
KR20190100200A (ko)	2016-11-22	2019-08-28	알로플렉스 바이오테라퓨틱스	동종이형 종양 세포 백신
US11185586B2 (en)	2016-11-22	2021-11-30	Alloplex Biotherapeutics, Inc.	Allogeneic tumor cell vaccine
CN111818940A (zh) *	2018-01-05	2020-10-23	安德烈亚斯·罗尔夫-乔纳斯·尼尔森	用作疫苗的内源性肿瘤衍生的环状rna及其蛋白质
US12246031B2 (en)	2018-02-13	2025-03-11	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
WO2019197965A1 (en)	2018-04-09	2019-10-17	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
CN113412120A (zh) *	2019-02-15	2021-09-17	Rjan控股公司	用作治疗性疫苗的自体癌症肿瘤相关染色体外环状dna
JP2023504659A (ja)	2019-12-03	2023-02-06	ニューボーゲン，インコーポレイティド	腫瘍細胞ワクチン

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5681562A (en)	1991-06-25	1997-10-28	Sidney Kimmel Cancer Center	Lymphokine gene therapy of cancer
AU677165B2 (en) *	1991-10-04	1997-04-17	Johns Hopkins University School Of Medicine, The	The regulation of systemic immune responses utilizing cytokines and antigens
DE4416784A1 (de)	1994-05-09	1995-11-30	Soft Gene Gmbh	Methode zur Anreicherung von Zellen, die durch ballistischen Transfer modifiziert wurden
DE4431401A1 (de) *	1994-08-24	1996-02-29	Max Delbrueck Centrum	Lebendvakzine gegen Tumorerkrankungen
DE19648625A1 (de)	1996-11-13	1998-05-14	Soft Gene Gmbh	Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
DE19746173A1 (de) *	1997-10-18	1999-04-22	Boehringer Ingelheim Int	Tumorvakzine
CN1100879C (zh)	1998-02-23	2003-02-05	上海东方肝胆外科医院	多基因转染的细胞株及其构建方法
DE19832840C1 (de)	1998-07-21	2000-06-08	Kerkmann Tucek Aida	Mittel zur Immuntherapie von Tumorerkrankungen
DE19935756A1 (de)	1999-07-27	2001-02-08	Mologen Forschungs Entwicklung	Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
DE10290185D2 (de) *	2001-01-31	2004-04-15	Mologen Forschungs Entwicklung	Tumorvakzine
WO2002100345A2 (en)	2001-06-11	2002-12-19	The Trustees Of The University Of Pennsylvania	Vaccines, immunotherapeutics and methods of using the same
DK1432439T3 (da)	2001-10-02	2006-04-03	Mologen Ag	Middel til forbedring af immunsvaret
WO2003039591A2 (de) *	2001-11-09	2003-05-15	Medigene Aktiengesellschaft	Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
AU2002356763A1 (en) *	2001-11-30	2003-06-10	Medigene Aktiengesellschaft	Use of a technically modified cell as a vaccine for treating tumoral disease
AU2003260243A1 (en)	2002-07-19	2004-03-03	Mologen Ag	Dna expression construct for multiple gene expression
DE10234739A1 (de)	2002-07-30	2004-02-12	Universitätsklinikum Hamburg-Eppendorf	Splicing-Variante des humanen p53-Proteins und deren Verwendung zur Herstellung pharmazeutischer Präparate zur Behandlung von Tumorerkrankungen
RU2354694C2 (ru) *	2003-12-30	2009-05-10	Мологен Аг	Аллогенное противоопухолевое терапевтическое средство
US20060165668A1 (en)	2004-12-10	2006-07-27	Liu Linda N	Genetically modified tumor cells as cancer vaccines

2004
- 2004-04-20 RU RU2006127428/13A patent/RU2354694C2/ru active
- 2004-04-20 CN CN2012103165007A patent/CN102994515A/zh active Pending
- 2004-04-20 EP EP04728317A patent/EP1699480B1/de not_active Expired - Lifetime
- 2004-04-20 JP JP2006545896A patent/JP4945247B2/ja not_active Expired - Fee Related
- 2004-04-20 BR BRPI0418157-3A patent/BRPI0418157A/pt active Search and Examination
- 2004-04-20 PT PT04728317T patent/PT1699480E/pt unknown
- 2004-04-20 DK DK04728317.1T patent/DK1699480T3/da active
- 2004-04-20 ES ES04728317T patent/ES2366694T3/es not_active Expired - Lifetime
- 2004-04-20 CN CNA2004800396643A patent/CN1921882A/zh active Pending
- 2004-04-20 AT AT04728317T patent/ATE512668T1/de active
- 2004-04-20 PL PL04728317T patent/PL1699480T3/pl unknown
- 2004-04-20 CN CN2012103159773A patent/CN103173460A/zh active Pending
- 2004-04-20 WO PCT/DE2004/000859 patent/WO2005063280A1/de active Application Filing
2006
- 2006-06-30 US US11/482,233 patent/US7635468B2/en not_active Expired - Lifetime
2009
- 2009-11-09 US US12/614,985 patent/US9345754B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN103173460A (zh)	2013-06-26
JP4945247B2 (ja)	2012-06-06
WO2005063280A1 (de)	2005-07-14
EP1699480A1 (de)	2006-09-13
RU2006127428A (ru)	2008-02-10
RU2354694C2 (ru)	2009-05-10
US7635468B2 (en)	2009-12-22
US9345754B2 (en)	2016-05-24
JP2007516985A (ja)	2007-06-28
EP1699480B1 (de)	2011-06-15
US20070160587A1 (en)	2007-07-12
BRPI0418157A (pt)	2007-04-17
PT1699480E (pt)	2011-08-30
ATE512668T1 (de)	2011-07-15
DK1699480T3 (da)	2011-10-10
CN1921882A (zh)	2007-02-28
CN102994515A (zh)	2013-03-27
US20100297189A1 (en)	2010-11-25
ES2366694T3 (es)	2011-10-24

Publication	Publication Date	Title
PL1699480T3 (pl)	2011-11-30	Allogeniczny przeciwnowotworowy czynnik terapeutyczny
IL169338A0 (en)	2007-07-04	Therapeutic formulations for the treatment of beta-amyloid related diseases
MXPA05008406A (es)	2006-02-17	Compuestos de amida tri(ciclo)-sustituida.
TW200505458A (en)	2005-02-16	1-amino 1h-imidazoquinolines
WO2005062881A3 (en)	2006-07-06	Gene therapy using transposon-based vectors
AU2003267203A8 (en)	2004-04-08	Method for administering thermotherapy to prevent the growth of tumors
PL374865A1 (pl)	2005-11-14	Leczenie zaburzeń związanych z TNF alfa
ATE240744T1 (de)	2003-06-15	Verwendung von csf-1-inhibitoren
YU71901A (sh)	2005-07-19	NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
MY140767A (en)	2010-01-15	Compounds, methods and compositions
IL207763A (en)	2014-07-31	Use of placental stem cells and umbilical cord blood to prepare a cure for disease and vulnerability
HK1040983A1 (en)	2002-06-28	Quinones for treatment of diseases.
EP1778186A4 (en)	2007-05-09	PROCESS FOR PREPARING POLY-ICLC AND USES THEREOF
SI1140168T1 (en)	2002-10-31	Vaccination against cancer
EP1663377A4 (en)	2011-09-07	THERAPEUTIC MEDICAL DEVICE, DELIVERY AND METHOD OF USE
MXPA05003818A (es)	2005-10-05	Perfilamiento de la expresion genica de muestras ffpe.
WO2003039591A3 (de)	2004-03-11	Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
WO2003105755A3 (en)	2004-03-18	ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
SI1509244T1 (sl)	2011-11-30	Nov postopek in spojina za izdelavo celične alogenične vakcine
WO2002060476A3 (de)	2003-01-23	Tumorvakzine
SI1596879T1 (sl)	2011-07-29	Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
MXPA03006742A (es)	2003-10-24	Uso de buprenorfina para la terapia de la incontinencia urinaria.
WO2003072019A3 (en)	2003-12-18	Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
EP1151756A4 (en)	2004-05-12	USE OF POLYACRYLAMIDE GEL FOR PRODUCING A CAPSULE IN THE TISSUE OF A MAMMAL ORGANISM, METHOD FOR CULTURING CELLS AND METHOD FOR TREATING ONCOLOGICAL DISEASES AND DIABETES MELLITUS
WO2003105754A3 (en)	2004-04-01	ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR B (VEGF-B) EXPRESSION